Abstract
NO is considered to be an ubiquitous endogenous system which takes part in bodys homeostatic regulations and in pathological events. NO derives from a) the actions of enzymes, the NO Synthases (NOS), which are constitutives (endothelial NOS (eNOS) and nervous NOS (nNOS)) and generate small amounts of NO and have homeostatic functions: and b) from the actions of inducible NOS (iNOS), which generate large amounts of NO and exert protective actions against noxious agents but also toxic effects (e.g. inhibition of enzymes) through the production of peroxynitrite (ONOO-). Modulation of the L-Arg / NO system may be used to obtain favourable therapeutic results, either by promoting (e.g. with NO donors) or by reducing (e.g. with NOS inhibitors) the production of NO. The present chapter will consider two approaches and four groups of potential therapeutic agents: 1) The stimulation of NO production with; a) agents which improve the efficiency of the Kallikrein-Kinin System; b) NO donors 2) The reduction of excessive NO production with: a) inhibitors of NO Synthases; b) agents that reduce the formation of reactive nitrogen / oxygen species (RNS / ROS).
Keywords: guanylate cyclase, no, no synthases, kallikrein-kinins, kinin receptors, no donors, nos inhibitors, cyclic gmp
Current Pharmaceutical Design
Title: Pharmacology of Nitric Oxide: Molecular Mechanisms and Therapeutic Strategies
Volume: 10 Issue: 14
Author(s): Regoli Domenico
Affiliation:
Keywords: guanylate cyclase, no, no synthases, kallikrein-kinins, kinin receptors, no donors, nos inhibitors, cyclic gmp
Abstract: NO is considered to be an ubiquitous endogenous system which takes part in bodys homeostatic regulations and in pathological events. NO derives from a) the actions of enzymes, the NO Synthases (NOS), which are constitutives (endothelial NOS (eNOS) and nervous NOS (nNOS)) and generate small amounts of NO and have homeostatic functions: and b) from the actions of inducible NOS (iNOS), which generate large amounts of NO and exert protective actions against noxious agents but also toxic effects (e.g. inhibition of enzymes) through the production of peroxynitrite (ONOO-). Modulation of the L-Arg / NO system may be used to obtain favourable therapeutic results, either by promoting (e.g. with NO donors) or by reducing (e.g. with NOS inhibitors) the production of NO. The present chapter will consider two approaches and four groups of potential therapeutic agents: 1) The stimulation of NO production with; a) agents which improve the efficiency of the Kallikrein-Kinin System; b) NO donors 2) The reduction of excessive NO production with: a) inhibitors of NO Synthases; b) agents that reduce the formation of reactive nitrogen / oxygen species (RNS / ROS).
Export Options
About this article
Cite this article as:
Domenico Regoli, Pharmacology of Nitric Oxide: Molecular Mechanisms and Therapeutic Strategies, Current Pharmaceutical Design 2004; 10 (14) . https://dx.doi.org/10.2174/1381612043384709
DOI https://dx.doi.org/10.2174/1381612043384709 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Context-Dependency of Relations Between Cardiovascular Phenotypes and Genes Involved in Sodium Homeostasis: Findings from the European Project on Genes in Hypertension
Current Hypertension Reviews Cellular Mechanisms of Bypass Vein Graft Arterialization and Approaches to Attenuate Graft Remodeling
Vascular Disease Prevention (Discontinued) Structural Basis of Resistance to Anti-Cytochrome bc<sub>1</sub> Complex Inhibitors: Implication for Drug Improvement
Current Pharmaceutical Design Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Immunopathology of Type 1 Diabetes and Immunomodulatory Effects of Stem Cells: A Narrative Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets Anesthetic Neuroprotection: Antecedents and An Appraisal of Preclinical and Clinical Data Quality
Current Pharmaceutical Design A Review of IGF1 Signaling and IGF1-related Long Noncoding RNAs in Chemoresistance of Cancer
Current Cancer Drug Targets Estrogen Regulation of MicroRNA Expression
Current Genomics Prognostic Parameters for Symptomatic Intracranial Hemorrhage after Intravenous Thrombolysis in Acute Ischemic Stroke in an Asian Population
Current Neurovascular Research Effects of Aging and Diet on Cardioprotection and Cardiometabolic Risk Markers
Current Pharmaceutical Design A Review on Recent Patents in Digital Processing for Cardiac Electric Signals (I): From Basic Systems to Arrhythmia Analysis
Recent Patents on Biomedical Engineering (Discontinued) Myocardial Infarction after Rituximab Treatment for Rheumatoid Arthritis: Is there a Link?
Current Pharmaceutical Design Synthesis of New Antibacterial Cubane-based Nanocomposite and its Application in Combination Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The Role of Mitochondria in Brain Aging and the Effects of Melatonin
Current Neuropharmacology Crosstalk Signalling Role in Modulation of Drugs Side Effects
Current Molecular Pharmacology Eosinophilopoiesis at the Cross-Roads of Research on Development, Immunity and Drug Discovery
Current Medicinal Chemistry Antiangiogenesis Drug Design: Multiple Pathways Targeting Tumor Vasculature
Current Medicinal Chemistry Prevention of Contrast Induced Nephropathy
Current Drug Therapy Atherosclerosis as an Inflammatory Disease
Current Pharmaceutical Design Leishmaniasis: Current Treatment and Prospects for New Drugs and Vaccines
Current Medicinal Chemistry